We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
Reversing runaway inflammation in the bone marrow could lead to major breakthroughs in treatments for some blood cancers, according to a new publication by scientists at Hackensack Meridian Health's Center for Discovery and Innovation.
While sitting in the dentist's office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea.
Korean researchers have observed cup-shaped red blood cells in the peripheral blood of a patient with myelodysplastic syndrome.
A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia, one of the most common forms of blood cancer.
A stem cell transplant - also called a bone marrow transplant - is a common treatment for blood cancers, such as acute myeloid leukemia.
Acute myeloid leukemia (AML) is a deadly blood cancer that originates in the bone marrow and kills most of its victims within five years. Chemotherapy has been the standard AML treatment for over 40 years, and while it often causes the cancer to go into remission, it rarely completely eliminates the cancerous cells, which then lead to disease recurrence in nearly half of treated patients.
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division.
Acute myeloid leukemia is the most common type of leukemia in adults. It is characterized by the pathological expansion of immature cells (myeloblasts) that invade the bone marrow and expand into the blood, affecting the production of the rest of the healthy cells.
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia (AML) - with high reliability.
The progression of cancer has been studied extensively, and the key steps in this journey have been well mapped, at least in some solid tumors: Lesions to genes that confer risk of cancer accumulate and alter normal cell behaviors, giving rise, scientists believe, to early stage cancer cells that eventually swamp normal cells and become deadly.